OOIR: Observatory of International Research

Papers

(The median citation count of Movement Disorders is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
John Michael Walshe (April 24, 1920–October 14, 2022)	536
	204
Stability of Mosaic Divergent Repeat Interruptions in X‐Linked Dystonia‐Parkinsonism	155
The Pattern and Stages of Atrophy in Spinocerebellar Ataxia Type 2: Volumetrics from ENIGMA‐Ataxia	139
Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters	132
The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?	106
Fixel‐Based Analysis Reveals Whole‐Brain White Matter Abnormalities in Cervical Dystonia	103
Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy	91
YY1: A New Gene for Childhood Onset Dystonia with Prominent Oromandibular‐Laryngeal Involvement?	90
Neuroinflammation in the Cerebellum and Brainstem in Friedreich Ataxia: An [¹⁸F]‐FEMPA PET Study	85
Motor Cortex Disinhibition Correlates with Olfactory Dysfunction in Parkinson's Disease	81
Substantia Nigra Elasticity Measurement Using Transcranial Shear Wave Elastography: A Potential Biomarker for Parkinson's Disease	80
Bidirectional Transcription at the PPP2R2B Gene Locus in Spinocerebellar Ataxia Type 12	78
Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait	76
Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy	74
α‐Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid‐Binding Property	69
A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease	66
May Infographic	64
Movement Disorders: Volume 40, Number 6, June 2025	63
Movement Disorders: Volume 40, Number 2, February 2025	62
Issue Information	62
Measuring Tremor—A Comparison of Automated Video Analysis, Neurophysiology, and Clinical Rating	62
The FDA Has Ended Required Blood Monitoring for Clozapine Use—Will This Impact the Management of Parkinson's Disease Psychosis?	61
Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals	61
X‐Linked Dystonia‐Parkinsonism (“Lubag”) May Present with Peripheral Synucleinopathy	61

The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure	60
In Memoriam Mahlon R. DeLong (1938–2024)	60
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers	57
The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease	57
Early Changes in Striatal Activity and Motor Kinematics in a Huntington's Disease Mouse Model	56
Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism	55
Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation	54
Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials	54
Obituary for Jan O. Aasly (1950–2022)	53
Author Index	52
	51
Thank you to Reviewers 2022	50
Central Involvement in Pure Autonomic Failure: Insights from Neuromelanin‐Sensitive Magnetic Resonance Imaging and ¹⁸F‐Fluorodopa‐Positron Emission Tomography	50
Downbeat Nystagmus in Episodic Ataxia Type 1 Associated with a Novel KCNA1 Mutation	49
Effect of Public Interest in Magnetic Resonance Imaging–Guided Focused Ultrasound on Enrolment for Deep Brain Stimulation	47
Diagnostic and Prognostic Value of External Anal SphincterEMGPatterns in Multiple System Atrophy	46
Reply to: “Application of the mPSPRS to the Salerno Cohort”	45
Cortical Functional Connectivity Changes in the Body‐First and Brain‐First Subtypes of Parkinson's Disease	44
Combining Skin α‐Synuclein Real‐Time Quaking‐Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease	44
Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease	44
In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN‐Related Parkinson's Disease	44
Lesion of the Subthalamic Nucleus Should Not be Labeled “Subthalamotomy”; A Plea for Anatomical Accuracy and Compliance with Historical Legacy	44
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity	44
Stress in Musicians with and Without Focal Dystonia Is Not Reflected in Limbic Circuit Activation	43
Exploration of Neurodegenerative Diseases Using Long‐Read Sequencing and Optical Genome Mapping Technologies	43
Navigating Visual Challenges: How Parkinson's Disease Alters Cognitive Priorities in Visual Search	43
	41
Research Priorities on the Role of α‐Synuclein in Parkinson's Disease Pathogenesis	41
Functional Movement Disorders and Drug‐Induced Movement Disorders	41
The Lows of High Reward: Choking Under Pressure	40
Re‐emergent Tremor in Parkinson's Disease: Evidence of Pathologic β and Prokinetic γ Activity	40
Substantiating the Short Burst Duration in Cortical Myoclonus	40
Novel In‐Frame FGF14 Deletion Causes Spinocerebellar Ataxia Type 27A: Clinical Response to Deep Brain Stimulation and 4‐Aminopyridine	40
A CGG Repeat Expansion in CSNK1E Associated with Progressive Myoclonic Epilepsy with Incomplete Penetrance	39
Reply to: “An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis”	38
Derivation and Validation of a Phenoconversion‐Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder	38
Reply to: “Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders: More Common than Expected”	38
Plant‐Based Dietary Patterns and Parkinson's Disease: A Prospective Analysis of the UK Biobank	38
De Novo and Dominantly Inherited SPTAN1 Mutations Cause Spastic Paraplegia and Cerebellar Ataxia	38
Genetic Determinants of Survival in Parkinson's Disease in the Asian Population	38
Movement Disorders: Volume 36, Number 11, November 2021	37
Patients with Allan‐Herndon‐Dudley Syndrome (MCT8 Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa Treatment	37
Issue Information	36
Movement Disorders: Volume 37, Number 9, September 2022	36
Issue Information	36
October Infographic	36
Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2‐Hydroxypropyl‐β‐Cyclodextrin Treatment	35
Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation	35
Compound Heterozygous Structural Variants in Cases with Unsolved PRKN‐Associated Parkinson's Disease	35
Spinal Cord Stimulation Failed to Improve Parkinson's Disease Symptoms in Randomized Crossover Double‐Blinded Evaluation	35

Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson's Disease	34
Paroxysmal Kinesigenic Dyskinesia Secondary to Brain Calcification with a Homozygous MYORG Mutation	34
Oligodendrocyte and Extracellular Matrix Contributions to Central Nervous System Motor Function: Implications for Dystonia	34
Unusual Age‐Dependent Behavior of Leukocytes Telomere Length in Friedreich's Ataxia	34
Secondary Paroxysmal Kinesigenic Dyskinesia with a CASR Mutation	34
Mitochondrial DNA Copy Number as a Potential Biomarker for the Severity of Motor Symptoms and Prognosis in Parkinson's Disease	34
Corrections to “A Machine‐Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design”	34
The Self‐Administered Screening Questionnaire for Parkinson's Disease‐Associated Psychosis (SASPAP)	33
Genetic Determined Iron Starvation Signature in Friedreich's Ataxia	33
Static Posture Instability as a Sensitive Biomarker for Motor Abnormalities in Pre‐ataxic Spinocerebellar Ataxia Type 3 Patients	33
Teaching an Old Drug a New Trick for Dystonia	33
Subthalamic Nucleus Activity during Cognitive Load and Gait Dysfunction in Parkinson's Disease	32
Ethnic Differences in Dystonia Prevalence and Phenotype	32
Issue Information	32
In Memoriam Gregor K. Wenning (1964–2024)	32
Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy	32
Digging into the Unknowns of the Human Genome Sequence: The T2T‐CHM13 Reference Assembly Release	32
August Infographic	31
February Infographic	31
Issue Information	31
Issue Information	31
Movement Disorders: Volume 38, Number 12, December 2023	31
Sex and Racial/Ethnic Differences in End‐of‐Life Care Preferences in Persons with Parkinson's Disease and Related Disorders	30
Low/High Multi‐Frequency Stimulation of the Subthalamic Nucleus Improves Verbal Fluency Maintaining Motor Control in Parkinson's Disease	30
Issue Information	30
¹⁸F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies	30
Movement Disorders: Volume 40, Number 3, March 2025	30
Reply to: “Early Onset Nonprogressive Generalized Dystonia Is Caused by Biallelic SHQ1 Variants”	30
Keyword Index	29
Parkinsonisms	29
Correction to “Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus”	29
Genotype–Phenotype Correlations for ATX‐TBP (SCA17): MDSGene Systematic Review	29
Epigenetic Drug Effects in Levodopa‐Treated Patients with Parkinson's Disease	29
Chromatic Pupillometry in Isolated Rapid Eye Movement Sleep Behavior Disorder	28
Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid	28
Pain in Multiple System Atrophy: A Community‐Based Survey	28
Potential Disease‐Modifying Effects of Ganglioside GM1 Pulse Treatment on Spinocerebellar Ataxia Type 3, a Parallel‐Group, Double‐Blind, Randomized, Controlled Trial	28
Deciphering the Janus‐Faced Nature of the Apolipoprotein Superfamily in Parkinsonian Neurodegeneration: Molecular Crosstalk Between the Astroglial Secretome and Neuronal Homeostasis	28
Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson's Disease	28
Practically Defined Off‐State Dyskinesia Following Repeated Intraputamenal Glial Cell Line–Derived Neurotrophic Factor Administration	27
Free‐Water Imaging in Friedreich Ataxia Using Multi‐Compartment Models	27
Neurodegeneration with Brain Iron Accumulation Disorders and Retinal Neurovascular Structure	27
Placebo and Nocebo Responses in Pharmacological Trials of Tic Disorders: A Meta‐Analysis	27
COVID‐19 Infection Enhances Susceptibility to Oxidative Stress–Induced Parkinsonism	27
Clearing the Smoke: What Protects Smokers from Parkinson's Disease?	26
A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis	26
Essential Tremor Suppression with a Novel Anti‐Tremor Orthosis: A Randomized Crossover Trial	26
A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ‐009	26
A Novel SPAST Mutation Results in Spastin Accumulation and Defects in Microtubule Dynamics	26
Juvenile‐Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review	26
Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review	25
GAA‐FGF14 Expansions and CACNA1A Variants: Phenotypic Overlap and Diagnostic Implications	25
Association between the Amplification Parameters of the α‐Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease	25
Comparison of Two α‐Synuclein Seed Amplification Assays for Discrimination of Parkinson Disease and Atypical Parkinsonism	25
Pandemic Tic‐like Behaviors Following Social Media Consumption	25
Defining the Importance of Minor Hallucinations in Parkinson's Disease	24
Structural Alterations in the Gray Matter Volume in Rapid‐Onset Dystonia‐Parkinsonism	24
Reply to: Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation	24
Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review	24
Whole‐Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy	24
	24
Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease	24
Tract‐Specific Spinal Cord Diffusion Tensor Imaging in Friedreich's Ataxia	24
CAG Repeat Expansion in THAP11 Is Associated with a Novel Spinocerebellar Ataxia	24
First Evidence for Disease‐Modifying Treatment of SLC20A2‐Related Primary Familial Brain Calcification	24
Reply to: Enhancing Clarity in Tremor Network Gene Expression Analysis	24
Multimodal Analysis of the Visual Pathways in Friedreich's Ataxia Reveals Novel Biomarkers	23
Obituary for Professor Hiroshi Shibasaki	23
Longitudinal Clinical and Biological Characteristics in Juvenile‐Onset Huntington's Disease	23
Familial Cerebellar Ataxia and Amyotrophic Lateral Sclerosis/Frontotemporal Dementia with DAB1 and C9ORF72 Repeat Expansions: An 18‐Year Study	23
Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations	23
Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings	23
Learning to Have a Long‐Duration Response	23
The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?	23
Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels	23
Differential Synaptic Loss in β‐Amyloid Positive Versus β‐Amyloid Negative Corticobasal Syndrome	23
Reply to: Heterogeneity of CSF1R‐RD: Genes, Environment, or Both?	23
Two London Memorials to “James Parkinson [1755–1824], Esq. Surgeon, Late of Hoxton‐Square”	23
GNAO1 Haploinsufficiency: The Milder End of the GNAO1 Phenotypic Spectrum	23
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease	22

Proteomic Profiling in Dystonia: The Next Frontier for Pathophysiology Research and Biomarker Exploration	22
Automated Motor Tic Detection: A Machine Learning Approach	22
No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts	22
Expanding the Allelic and Clinical Heterogeneity of Movement Disorders Linked to Defects of Mitochondrial Adenosine Triphosphate Synthase	22
Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease	22
Investigating the Brain Mechanisms of Externally Cued Sit‐to‐Stand Movement in Parkinson's Disease	22
Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study	21
Issue Information	21
Long‐Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia	21
Waveform‐Based Analysis of Head Tremor Using a Marker‐Less Tracking Algorithm with 2D‐Video: Evaluation of Sinusoidality and Rhythmicity	21
Early‐Onset Movement Disorder Syndrome Caused by Biallelic Variants in PDE1B Encoding Phosphodiesterase 1B	21
Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease	21
Movement Disorders: Volume 38, Number 9, September 2023	21
Reply to: “Refutation of the αSyn‐SAA‐Based Staging for Parkinson's Progression (Neuronal α‐Synuclein Disease‐Integrated Staging System [NSD‐ISS])”	21
On‐Demand Cueing for Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial	21
Plasma Phosphorylated Tau181 as a Biomarker for Alzheimer's Disease Co‐Pathology in Lewy Body Disease	21
February Infographic	21
Movement Disorders: Volume 39, Number 9, September 2024	21
Where Do Parkinson's Disease Patients Look While Walking?	21
Diffusion Tensor Imaging‐Along the Perivascular‐Space Index Is Associated with Disease Progression in Parkinson's Disease	21
April Infographic	20
Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study	20
A Short Progressive Supranuclear Palsy Quality of Life Scale: Data from the PSP‐NET	20
March Infographic	20
Brain Imaging Phenotypes Associated with Polygenic Risk for Essential Tremor	20
	20
Keyword Index	20
Movement Disorders: Volume 38, Number 11, November 2023	20
	20
Step Width Haptic Feedback for Gait Stability in Spinocerebellar Ataxia: Preliminary Results	19
Anodal Cerebellar Transcranial Direct Current Stimulation Reduces Motor and Cognitive Symptoms in Friedreich's Ataxia: A Randomized, Sham‐Controlled Trial	19
Deep Brain Stimulation Improves Parkinson's Disease‐Associated Pain by Decreasing Spinal Nociception	19
Issue Information	19
Prasinezumab: A Bayesian Perspective on Its Efficacy	19
Blood‐Based α‐Synuclein Seeding—A New Era for Identifying Parkinsonian Syndromes	19
Reply to Letter to the Editor‐MDS‐23‐0498.R2/MDS‐24‐0318.R1	19
Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell‐Derived A9 Dopaminergic Neurons	19
Mutation Screening of TFG in α‐Synucleinopathy and Amyotrophic Lateral Sclerosis	19
Circulating Extracellular Vesicles as a Potential Mediator of Synuclein Pathology in the Gut	19
Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility?	19
Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons	18
Pathophysiological Role of Primary Motor Cortex in Essential Tremor	18
Automated Quantification of Eye Tics Using Computer Vision and Deep Learning Techniques	18
	18
mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double‐Blind, Placebo‐Controlled Futility Trial and 1‐Year Biomarker Longitudinal Analysis	18
Depressive Symptoms and Suicidal Thoughts in Restless Legs Syndrome	18
Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof‐of‐Principle Issues from a Randomized Controlled Study	18
Mendelian Randomization Studies: A Path to Better Understand Sex and Gender Differences in Parkinson's Disease?	18
Erythrocytic α‐Synuclein and the Gut Microbiome: Kindling of the Gut‐Brain Axis in Parkinson's Disease	18
	18
Comparative Study of Focused Ultrasound Unilateral Thalamotomy and Subthalamotomy for Medication‐Refractory Parkinson's Disease Tremor	18
Endoscopic Characteristics of Dysphagia in Multiple System Atrophy Compared to Parkinson's Disease	18
Re‐Analysis of the STEADY‐PD II Trial—Evidence for Slowing the Progression of Parkinson's Disease	18
Diagnosis and Outcomes of Late‐Onset Wilson's Disease: A National Registry‐Based Study	18
Catatonia: What Else Matters?	18
Autosomal Recessive Cerebellar Ataxias in Europe: Frequency, Onset, and Severity in 677 Patients	18
Bidirectional Interplay between Deep Brain Stimulation and Cognition in Parkinson's Disease: A Systematic Review	17
Surgery Imaging and Technology	17
Clinical Utility of Neurophysiologic Classification (and Declassification) of Myoclonus	17
IRF2BPL‐Related Disorder, Causing Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech and Seizures (NEDAMSS) Is Characterized by Pathology Consistent	17
Advancing Parkinson's Research: Considerations and Future Directions	17
Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease	17
Genetic Analysis of GCA Repeats in the GLS Gene: Implications for Undiagnosed Ataxia and Spinocerebellar Ataxia 3 in Mainland China	17
Viewpoint on Milestones for Fellowship Training in Movement Disorders	17
High Pesticide Exposure Events and Dream‐Enacting Behaviors Among US Farmers	17
Globus Pallidus Internus (GPi) Neuromodulation is Not Effective in Unverricht–Lundborg Disease to Control Myoclonia	17
The Pain in Dystonia Scale (PIDS)—Development and Validation in Cervical Dystonia	17
Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA‐PD Study	17
A GNAI1 Pathogenic Variant in a Case with GNAO1‐Isolated Dystonia: A Modifier of Disease Severity?	17
Motor Cortical Network Excitability in Parkinson's Disease	17
Top Movement Disorders Journal Reviewers from 2024	17
Brain and Cerebrospinal Fluid α‐Synuclein Real‐Time Quaking‐Induced Conversion Identifies Lewy Body Pathology in LRRK2‐PD	16
Redefining Bradykinesia	16
Further Directions in Mindfulness‐Based Interventions for Tic Disorders	16
A 10‐Year Community‐Based Study of Leucine‐Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease	16
Computerized Cognitive Training Increases Gray Matter Volumes in Huntington's Disease: A Pilot Study	16
Impaired Glymphatic Clearance, Measured Using Diffusion Tensor Image Analysis Along the Perivascular Space (DTI‐ALPS), is Linked to Poor Cognitive Outcomes in Parkinson's Disease	16
Bilateral Simultaneous Magnetic Resonance–Guided Focused Ultrasound Pallidotomy for Life‐Threatening Status Dystonicus	16
The Dawn of Precision Medicine for Deep Brain Stimulation in Parkinson's Disease?	16
Disentangling the Connection Between Neurodevelopment and Neurodegeneration in Huntington's Disease	16
Reply to: Comment on De Giorgis et al. “Randomized Phase 3 Study of Triheptanoin for Glut1 Deficiency Syndrome–Associated Paroxysmal Movement Disorders”	16
No Association Between Rare TWNK Variants and Parkinson's Disease in European Cohorts	16
Impact of Magnetic Resonance Imaging Markers on the Diagnostic Performance of the International Parkinson and Movement Disorder Society Multiple System Atrophy Criteria	16
An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis	16
Shaking Up Ataxia: FGF14 and RFC1 Repeat Expansions in Affected and Unaffected Members of a Chilean Family	16
Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome	15
Differences in Sex‐Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism	15
Diffusion Magnetic Resonance Imaging Microstructural Abnormalities in Multiple System Atrophy: A Comprehensive Review	15
Cross‐Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease	15
Reliability of Neuroimaging and Neurophysiological Tremor Features in Parkinson's Disease	15
Beta Burst Characteristics and Coupling within the Sensorimotor Cortical‐Subthalamic Nucleus Circuit Dynamically Relate to Bradykinesia in Parkinson's Disease	15
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy	15
Pilot Study of Acute Behavioral Effects of Pallidal Burst Stimulation in Parkinson's Disease	15
Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance–Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study	15
Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus	15